Evidence map›Paper›PMID 32183160›Full record

ArticleCancers2020

Vitamin D3 Metabolites Demonstrate Prognostic Value in

Tatiana Shaurova, Grace K Dy, Sebastiano Battaglia, Alan Hutson, Letian Zhang, Yunkai Zhang, Christine M Lovly, Mukund Seshadri, David W Goodrich, Candace S Johnson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Tatiana ShaurovaDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Grace K DyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Sebastiano BattagliaCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Alan HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Letian ZhangDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Yunkai ZhangDepartment of Medicine and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Christine M LovlyDepartment of Medicine and Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Mukund SeshadriDepartment of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
David W GoodrichDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Candace S JohnsonDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Pamela A HershbergerDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Roswell Park Comprehensive Cancer Center · USVanderbilt University Medical Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancerR01CA234162 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOODRICH, DAVID W. · 2019 to 2024
$3.0M
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancerR01CA207757 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ELLIS, LEIGH, GOODRICH, DAVID W. · 2016 to 2020
$2.8M
Impact of Vitamin D on the Chemopreventive Efficacy of Erlotinib against Oral CancerR01DE024595 · NIDCR · ROSWELL PARK CANCER INSTITUTE CORP · PI SESHADRI, MUKUND · 2016 to 2020
$2.4M
Precision vitamin D supplementation as a novel approach to prevent lung cancer progressionR03CA249411 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HERSHBERGER, PAMELA A · 2020 to 2021
$175k
NCI NIH HHS R01 CA207757NCI NIH HHS R01 CA234162NCI NIH HHS R03 CA249411NIDCR NIH HHS R01 DE024595NIH HHS DE024595NIH HHS P30CA016056
6 · The paper itself

Abstract

EGFR tyrosine kinase inhibitors (EGFR TKIs) are the standard of care treatment for patients with

Indexed as

EGFRepithelial–mesenchymal transitionlung cancertyrosine kinase inhibitorvitamin D

Identifiers

PMID32183160
PMCPMC7140110
OpenAlexW3011554935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.